^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Published date:
06/01/2021
Excerpt:
Subgroup analysis by PD-L1 tumor expression status indicated better efficacy outcomes in patients with PD-L1+ tumors versus those with PD-L1− tumors [ORR, 28.4% (95% CI: 18.5–40.1) vs 17.3% (95% CI: 9.6–27.8); PFS, 4.2 months (95% CI: 3.5–6.1) vs 3.9 months (95% CI: 2.3–4.4)...in patients with PD-L1+ tumors, the study-drug combination also demonstrated promising antitumor activity in patients with PD-L1− tumors. These results support further clinical development of eribulin plus pembrolizumab as a potential antitumor strategy for patients with mTNBC.
DOI:
10.1158/1078-0432.CCR-20-4726
Trial ID:
